In a recent development, medical experts have called for a comprehensive national vaccine program for adults, mirroring the existing initiatives for children. This proposal extends to making the shingles vaccine free for older adults, a move that could significantly impact public health and healthcare costs. The call for action comes from renowned medical professionals, including Professor Ronan Collins, a consultant geriatrician and stroke physician at the Royal College of Physicians of Ireland. He emphasizes the profound impact of vaccination on modern medicine, highlighting its role in ensuring healthy aging and preventing cardiovascular diseases, strokes, and dementia.
The focus on adult vaccination programs is a stark contrast to the robust childhood vaccination initiatives in Ireland. Professor Collins argues that vaccination should be a cornerstone of healthcare, particularly for older adults, to combat age-related health issues. The discussion centers around the shingles vaccine, a relatively new addition to the medical arsenal against a painful and potentially serious infection caused by the chickenpox virus. While the vaccine has shown remarkable efficacy, it is currently not available on the public health system, leaving older adults with a substantial financial burden.
Professor Luke O'Neill, from the School of Biochemistry and Immunology at Trinity Biomedical Sciences Institute, provides further insights. He notes that approximately one in ten older adults is at risk of developing shingles annually, and the vaccine has demonstrated effectiveness in protecting against Alzheimer's and heart disease. O'Neill advocates for making the Shingrix vaccine free for those over 65, citing potential savings and increased uptake. A 70% uptake rate, with an estimated 10,000 cases annually, could result in significant cost savings of up to €8 million annually.
The issue of vaccine accessibility is further emphasized by Active Retirement Ireland (ARI). ARI's Head of Policy and Advocacy, Alison Bough, highlights the disparity between recommendations and access. The National Immunisation Advisory Committee has recommended the shingles vaccine for adults aged 65 and above, yet it remains privately available and unaffordable for many. Bough points out that a simple border crossing to Northern Ireland provides access to a publicly funded program, underscoring the inequity in the current system. The petition signed by over 20,000 ARI members underscores the public demand for fair, state-supported access to the shingles vaccine.
The Health Information and Quality Authority (HIQA) study adds to the growing body of evidence supporting the vaccine's safety and effectiveness. However, the high cost of the vaccine raises concerns about its cost-effectiveness, prompting calls for government intervention to make it publicly funded or state-supported. Bough emphasizes the long-term consequences of shingles for older adults, emphasizing the need for preventive measures and equitable access to healthcare.
In conclusion, the call for a national adult vaccine program and the free shingles vaccine for older adults is a significant development in public health. It highlights the need for a comprehensive approach to healthcare, addressing both preventive measures and equitable access. As the medical community continues to advocate for these changes, the future of adult vaccination in Ireland looks set to undergo a transformative shift, potentially improving health outcomes and reducing healthcare costs.
